Advertisement


Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Opportunities to Optimize Cancer Policies Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Advertisement